Dr. Holland is an Assistant Professor at Emory in the School of Medicine (Department of Medicine, Division of Infectious Diseases). His research aims at improving the efficiency of clinical trials. His previous projects have focused on the use of decision analysis in the planning phase of clinical trials in an effort to identify the most economically viable potential regimens prior to conducting large-scale studies. In particular, he collaborated with scientists and economists from the Centers for Disease Control and Prevention on cost-effectiveness analyses that have informed current guidelines for the treatment of latent tuberculosis infection and identified areas for future research that are of high value to current policymakers. Currently, he is working on projects that use alternative analytic techniques, primarily Bayesian designs, to improve the efficiency of clinical trials, both in terms of time and money. His clinical interests include treatment and prevention of tuberculosis, sexually transmitted infection, and HIV (including pre-exposure prophylaxis).
Dr. David P. Holland, MD, MHS
- Infectious Disease
- Internal Medicine
- ABMS Internal Medicine
- James Eastwood, MD
Education & Training
- Medical School: Emory University School of Medicine
- Residency: Emory Saint Joseph's Hospital
Honors & Awards
Pfizer Travel Award (American Thoracic Society), 2008
Barton F. Haynes Early Career Research Award, 2009
Nicolls DJ, Bala J, King M, Holland D, del Rio C. Intracranial Tuberculomas Developing while on Therapy for Pulmonary Tuberculosis. Lancet Infect Dis. 2005 Dec;5(12):795-801. 2.
Holland DP, Hamilton CD, Weintrob AC, Engemann JJ, Fortenberry ER, Peloquin CA, and Stout JE. Therapeutic drug monitoring of anti-mycobacterial medications in patients with tuberculosis and advanced human immunodeficiency virus infection. Pharmacotherapy. 2009 May;29(5):503-10. 3.
Holland DP, Sanders GD, Hamilton CD, and Stout JE. Costs and cost effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med. 2009 Jun 1;179(11):1055-60. PMC2689913. 4.
Crochet JR, Hawkins KC, Holland DP, Copeland SD. Diagnosis of pelvic tuberculosis in a patient with tubal infertility. Fertil Steril. 2011 Jan;95(1):289.e17-20 5.
Holland DP, Person AK, Stout JE. Did the “Great Recession” Produce a Depression in Tuberculosis Incidence? Int J Tuberc Lung Dis. 2011 May;15(5):700-702. 6.
Holland DP, Sanders GD, Hamilton CD, and Stout JE. Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. PLoS One. 2011;6(7):e22276. 7.
Goswami ND, Hecker E, Holland DP, Naggie S, Cox GM, Mosher A, Turner D, Torres Y, Vickery C, Ahearn MA, Blain ML, Rasmussen P, Stout JE. Feasibility and willingness-to-pay for integrated community-based tuberculosis testing. BMC Infect Dis. 2011 Nov 2;11:305. 8.
Goswami ND, Hecker EJ, Vickery C, Ahearn MA, Cox GM, Holland DP, Naggie S, Piedrahita C, Mosher A, Torres Y, Norton BL, Suchindran S, Park PH, Turner D, Stout JE. Geographic Information System-based Screening for TB, HIV, and Syphilis (GIS-THIS): A Cross-Sectional Study. PLoS One. 2012;7(10):e46029. doi: 10.1371/journal.pone.004602. 9.
Holland DP, Sanders GD, Hamilton CD, and Stout JE. Strategies for treating latent multiple-drug resistant tuberculosis: A decision analysis. PLoS One. 2012;7(1): e30194. 10.
Park PH, Holland DP, Wade A, Goswami ND, Bissette D, Stout JE. Public health costs for tuberculosis suspects in Wake County, North Carolina, United States. Int J Tuberc Lung Dis. 2013;17(6):759–63. 11.
Shepardson D., Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, Tian X, Borisov, AS, Shang N, Heilig CM, Sterling TR, Villarino ME, MacKenzie WR. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. Int J Tuberc Lung Dis. 2013;17(1):1531-7. 12.
Johnson M, Stout JE, Benator D, Whitworth W, Holland DP. Media matters: Modeling the impact of solid media performance on tuberculosis trial sample size requirements. Int J Tuberc Lung Dis. 2016 May;20(5):600-4. 13.
Holland DP, Hamilton CD, Stout JE. Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: A decision analysis. Int J Tuberc Lung Dis. 2016 Jun;20(6):827-31. 14.
Powell KM, VanderEnde DS, Holland DP, Haddad MB, Yarn B, Yamin AS Mohamed O, Sales RMF, DiMiceli, LE, Burns-Grant G, Reaves EJ, Gardener TJ, Ray SM. Consequences of an outbreak of drug-resistant Mycobacterium tuberculosis among homeless persons in Atlanta, Georgia. Public Health Rep. 2017 Mar/Apr;132(2):231-240. 15.
Connors WJ, Hussen SA, Holland DP, Mohamed O, Andes KL, Goswami ND. Homeless shelter context and tuberculosis illness experiences during a large outbreak in Atlanta, Georgia. Public Health Action. 2017 Sep;7(3):224-30. 16.
Belknap R, Holland D, Feng PJ, Millet JP, Caylà JA, Martinson N, Wright A, Chen MP, Moro RN, Scott NA, Arevalo B, Miro JM, Villarino E, Borisov AS, Tuberculosis Trials Consortium. Weekly Isoniazid and rifapentine self-administered with or without text reminders vs directly-observed for latent tuberculosis infection (iAdhere): A randomized clinical trial. Ann Intern Med. 2017 Nov;167(9):687-97. 17.
Schechter MC, Bizune D, Kagel M, siangonya B, Heidelburg R, Machaidze M, Holland DP, Oladele A, Wang YF, Rebodello PA, Ray SM Kempker RR. Time to Sputum Culture Conversion and Treatment Outcomes among Patients with Isoniazid-Resistant Tuberculosis in Atlanta, Georgia. Clin Inf Dis. E-pub ahead of print. 18.
Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z, Vernon A, Chaisson RE, on behalf of the Tuberculosis Trials Consortium. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006 Aug 1;174(3):331-8. 19.
Sandman L, Mosher A, Khan A, Tapy J, Condos R, Ferrell S, Vernon A; on behalf of the Tuberculosis Trials Consortium. Quality assurance in a large clinical trials consortium: the experience of the Tuberculosis Trials Consortium. Contemp Clin Trials. 2006 Dec;27(6):554-60. 20.
Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, Nuermberger EL, Villarino M, Vernon A, Chaisson RE, on behalf of the Tuberculosis Trials Consortium. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med. 2009 Aug;180(3):273-80. 21.
Stout JE, Kosinski AS, Hamilton CD, Goodman PC, Mosher A, Menzies D, Schluger N, Khan A, Johnson JL; on behalf of the Tuberculosis Trials Consortium. Effect of improving the quality of radiographic interpretation on the ability to predict pulmonary tuberculosis relapse. Acad Radiol. 2010 Feb;17(2):157-62. 22.
Nahid P, Bliven EE, Kim EY, Mac Kenzie WR, Stout JE, Diem L, Johnson JL, Gagneux S, Hopewell PC, Kato-Maeda M; on behalf of the Tuberculosis Trials Consortium. Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis. PLoS One. 2010 May 20;5(5):e10753.. 23.
Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR Jr, Chaisson RE; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011; 365(23): 2155-2166. 24.
Bliven-Sizemore EE, Johnson JL, Goldberg S, Burman WJ, Villarino ME, Chaisson RE; Tuberculosis Clinical Trials Consortium. Effect of HIV infection on tolerability and bacteriologic outcomes of tuberculosis treatment. Int J Tuberc Lung Dis. 2012 Apr;16(4):473-9. 25.
Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015 Mar;169(3):247-55. 26.
Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Drobeniuc J, Bock N, Villarino ME; TB Trials Consortium. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int J Tuberc Lung Dis. 2015 Sep;19(9):1039-44.